Rayyan Therapeutics, based in Hamilton, Ontario, is a biopharmaceutical company focused on developing a novel drug for cardiovascular diseases (CVD). Using patented technology, the drug targets blood clot prevention and dissolution, addressing severe CVD complications. The company aims to reduce global CVD-related deaths, offering hope to patients by improving life expectancy and quality of life.